What is Microbion?
Microbion is dedicated to pioneering a new class of therapeutics targeting microbial bioenergetic pathways. Their innovative approach aims to combat the growing threat of antibiotic resistance and treat infections that are currently intractable. The company's pipeline is designed to address unmet medical needs in infectious diseases, leveraging a deep understanding of microbial metabolism. This strategic focus positions Microbion at the forefront of antimicrobial research and development, seeking to provide life-saving solutions in a critical healthcare area.
How much funding has Microbion raised?
Microbion has raised a total of $46.5M across 6 funding rounds:
Private Equity
$932K
Private Equity
$1.2M
Unspecified
$100K
Private Equity
$25M
Other Financing Round
$17.1M
Private Equity
$2.1M
Private Equity (2010): $932K, investors not publicly disclosed
Private Equity (2012): $1.2M, investors not publicly disclosed
Unspecified (2014): $100K supported by Undisclosed
Private Equity (2016): $25M featuring GF Securities and Quark Venture
Other Financing Round (2020): $17.1M backed by Cystic Fibrosis Foundation and Carb-X
Private Equity (2022): $2.1M with participation from MTEC companies
Key Investors in Microbion
MTEC companies
MTEC companies is dedicated to advancing medical innovation by facilitating the rapid deployment of innovative medical technologies that enhance the health of both military personnel and civilians. Their initiatives include funding opportunities, guidance through government processes, and active participation in shaping the future of medical technology.
Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is a non-profit organization established to provide the means to cure cystic fibrosis and ensure that those living with CF live long and productive lives. They invest in research and development for treatments.
GF Securities
GF Securities is a financial services company that provides investment banking, brokerage, and asset management services. Their investment in Microbion suggests a strategic interest in the biotechnology sector.
What's next for Microbion?
With the recent influx of major strategic investment and substantial overall capital, Microbion is poised to accelerate its clinical development programs. The company is expected to advance its lead candidates through rigorous testing and regulatory pathways, aiming to bring its novel therapies to patients. This significant backing will likely fuel further research, expand its scientific team, and support the scaling of its operations to meet the demands of clinical trials and potential commercialization. The enterprise-level funding suggests confidence from investors in Microbion's technology and its potential to address a significant global health challenge.
See full Microbion company page
